
SLET 90% cheaper than CLET
A simplified version of a treatment pioneered in India to treat limbal stem cell deficiency (LSCD) has demonstrated comparable efficacy to its predecessor but at just 10% of the cost, according to a paper published in the British Journal of Ophthalmology.










